Clinical Value of Combined Detection of Serum sTim-3 and Pepsinogen for Gastric Cancer Diagnosis.
T cell immunoglobulin and mucin domain molecule 3
biomarker
gastric cancer
time-resolved fluorescence immunoassay
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2021
2021
Historique:
received:
13
07
2021
accepted:
27
09
2021
entrez:
22
10
2021
pubmed:
23
10
2021
medline:
23
10
2021
Statut:
epublish
Résumé
The present study aimed to evaluate the clinical value of the combined detection of soluble T cell immunoglobulinand mucin domain molecule 3 (sTim-3) and pepsinogen (PG) in sera for gastric cancer (GC) diagnosis. The double antibody sandwich method was used to establish a highly sensitive time-resolved fluorescence immunoassay for the detection of sTim-3. Serum sTim-3, PGI, and PGII levels in 149 GC patients (123 first-diagnosis GC patients and 26 post-GC patients), 81 patients with benign gastric disease (BGD), and 73 healthy controls were quantitatively detected. The clinical diagnostic value of the combined detection of sTim-3 and PG in GC was analyzed. Serum sTim-3 levels in GC (20.41 ± 9.55 ng/mL) and BGD (16.50 ± 9.76 ng/mL) patients were significantly higher (P < 0.001) than those in healthy controls (9.22 ± 3.40 ng/mL). Combined detection of sTim-3 and PGI/PGII (AUC: 0.9330, sensitivity: 86.44%, and specificity: 91.78%) showed a high diagnostic value for GC. When the level of PGI/PGII was less than 12.11 and that of sTim-3 was greater than 14.30 ng/mL, the positive rate of the control group was reduced to 0%, and the positive detection rate of GC was 54.47%. In addition, in post-operative patients, serum sTim-3 levels in the recurrence group (33.56 ± 4.91 ng/mL) were significantly higher than those in the no recurrence group (11.95 ± 5.16 ng/mL). sTim-3 levels in BGD and GC sera were significantly higher than those in the control group sera. Additionally, sTim-3 serum levels can predict recurrence in post-operative patients. Compared with PG alone, the combined detection of serum PG and sTim-3 can significantly improve the detection sensitivity and specificity of BGD and GC.
Identifiants
pubmed: 34675671
doi: 10.2147/CMAR.S328312
pii: 328312
pmc: PMC8517425
doi:
Types de publication
Journal Article
Langues
eng
Pagination
7759-7769Informations de copyright
© 2021 Chen et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Medicine (Baltimore). 2017 Jul;96(29):e7603
pubmed: 28723806
Oncoimmunology. 2016 Nov 28;6(1):e1261241
pubmed: 28197385
Dig Liver Dis. 2017 May;49(5):500-506
pubmed: 28057446
BMC Med Genet. 2020 Feb 10;21(1):28
pubmed: 32041551
Medicine (Baltimore). 2019 Jan;98(4):e14240
pubmed: 30681610
Oncotarget. 2017 May 9;8(19):31705-31713
pubmed: 28423646
PLoS One. 2020 Apr 9;15(4):e0230064
pubmed: 32271765
Mol Cancer. 2019 Nov 6;18(1):155
pubmed: 31690319
Ann Clin Lab Sci. 2017 May;47(3):260-263
pubmed: 28667025
Gut. 2002 Jan;50(1):13-8
pubmed: 11772960
J Immunol. 1971 Apr;106(4):962-8
pubmed: 4396533
PLoS One. 2015 Nov 10;10(11):e0142080
pubmed: 26556485
Neoplasma. 2019 Jul 23;66(4):637-640
pubmed: 31058531
Gastroenterology. 2003 Dec;125(6):1636-44
pubmed: 14724815
FEBS Open Bio. 2016 Jul 09;6(8):807-15
pubmed: 27516959
Immunol Invest. 2015;44(6):578-89
pubmed: 26214042
Med J Islam Repub Iran. 2014 Dec 16;28:150
pubmed: 25695008
Oncol Lett. 2019 Feb;17(2):1461-1466
pubmed: 30675200
Gastric Cancer. 2012 Apr;15(2):154-61
pubmed: 21892754
J Clin Lab Anal. 2020 Jun;34(6):e23248
pubmed: 32077157
Cell Biol Int. 2015 Apr;39(4):388-99
pubmed: 25492803
Hematology. 2020 Dec;25(1):125-133
pubmed: 32153257
Cell Immunol. 2017 Mar;313:43-51
pubmed: 28110884
DNA Cell Biol. 2013 Nov;32(11):648-53
pubmed: 24007284
Semin Oncol. 2019 Aug - Oct;46(4-5):372-379
pubmed: 31733828
Gastric Cancer. 2019 Jan;22(1):104-112
pubmed: 29934751
Am J Clin Pathol. 2012 Jun;137(6):978-85
pubmed: 22586058
Sci Rep. 2017 Nov 10;7(1):15280
pubmed: 29127350
J Gastrointest Cancer. 2018 Mar;49(1):57-62
pubmed: 28028765
BMC Clin Pathol. 2013 Sep 02;13(1):22
pubmed: 24004680
PLoS One. 2013;8(1):e53834
pubmed: 23335978
Lancet. 2020 Aug 29;396(10251):635-648
pubmed: 32861308
Oncol Lett. 2013 Aug;6(2):490-494
pubmed: 24137353
Immunol Invest. 2017 Feb;46(2):134-148
pubmed: 27911104
Cancer Control. 2020 Apr-Jun;27(2):1073274820922559
pubmed: 32379490
J Surg Oncol. 2015 Sep;112(4):430-5
pubmed: 26265374
PLoS One. 2012;7(2):e30676
pubmed: 22363469
J Clin Gastroenterol. 2019 May/Jun;53(5):e186-e193
pubmed: 29369241
BMC Gastroenterol. 2013 May 14;13:87
pubmed: 23672279
Cancer Immunol Res. 2015 Sep;3(9):999-1007
pubmed: 25783986
Asian Pac J Cancer Prev. ;18(3):765-770
pubmed: 28441784
Front Oncol. 2019 Nov 05;9:1159
pubmed: 31750248
World J Clin Oncol. 2014 May 10;5(2):170-6
pubmed: 24829865
J Immunol. 2006 Feb 1;176(3):1411-20
pubmed: 16424168